Get the Stockscreener App
0.80
0.00%
0.00
After Hours:
.79
-0.01
-1.25%
Durect Corp stock is traded at $0.80, with a volume of 99,003.
It is up +0.00% in the last 24 hours and down -0.73% over the past month.
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
See More
Previous Close:
$0.80
Open:
$0.816
24h Volume:
99,003
Relative Volume:
1.27
Market Cap:
$24.83M
Revenue:
$8.59M
Net Income/Loss:
$-17.07M
P/E Ratio:
-1.3115
EPS:
-0.61
Net Cash Flow:
$-21.90M
1W Performance:
+0.00%
1M Performance:
-0.73%
6M Performance:
-41.61%
1Y Performance:
-32.20%
1-Day Range:
$0.80
$0.816
1-Week Range:
$0.7768
$0.8671
52-Week Range:
$0.701
$1.88
Durect Corp Stock (DRRX) Company Profile
Name
Durect Corp
Sector
Phone
(408) 777-1417
Address
10240 BUBB ROAD, CUPERTINO, CA
Compare DRRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.80 | 24.83M | 8.59M | -17.07M | -21.90M | -0.61 |
|
ZTS
Zoetis Inc
|
163.75 | 73.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.13 | 47.80B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.37 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.67B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.53 | 13.99B | 612.78M | -86.37M | -62.91M | -0.87 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-12-20 | Initiated | ROTH Capital | Buy |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jan-31-20 | Initiated | B. Riley FBR | Buy |
| Nov-18-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-18 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-20-17 | Reiterated | Laidlaw | Buy |
| Oct-20-17 | Downgrade | Stifel | Buy → Hold |
| Jul-12-17 | Upgrade | Stifel | Hold → Buy |
| Feb-28-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-16 | Initiated | Rodman & Renshaw | Buy |
| May-01-15 | Reiterated | Cantor Fitzgerald | Buy |
| May-01-15 | Reiterated | Stifel | Buy |
| Mar-25-13 | Initiated | Stifel | Buy |
| Nov-01-12 | Downgrade | C.K. Cooper | Buy → Hold |
| Aug-17-12 | Initiated | C.K. Cooper | Buy |
| Jun-23-09 | Initiated | Caris & Company | Buy |
| Mar-26-09 | Initiated | Wedbush Morgan | Hold |
View All
Durect Corp Stock (DRRX) Latest News
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - Quantisnow
DURECT Q4 Earnings Preview: Key Financial Results and Strategic Updates Coming March 26 - StockTitan
StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Is Expected To Breakeven In The Near Future - Simply Wall St
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld Online
Larsucosterol flops on clinical benefit in phase 2b alcohol-associated hepatitis trial - Healio
DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
The R&D Dept.: Local patent roundup for 2.26.25 - RichmondBizSense
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com - Defense World
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - Stockhouse Publishing
DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Durect (DRRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Geode Capital Management LLC Has $429,000 Holdings in DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT faces Nasdaq delisting over share price - Investing.com
New Strong Buy Stocks for January 9th - Yahoo Finance
Reviewing Acerus Pharmaceuticals (OTCMKTS:TRLPF) and DURECT (NASDAQ:DRRX) - Defense World
Microbial Products Market Size to Hit USD 351.42 Bn by 2034 - Precedence Research
Durect (DRRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
DURECT Corp expected to post a loss of 17 cents a shareEarnings Preview - XM
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
DURECT Corp sells ALZET product line to Lafayette - TradingPedia
Durect announces sale of Alzet line of osmotic pumps to LIC for $17.5M - TipRanks
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million - PR Newswire
DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corporation reports Q3 2024 financials - Investing.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... - Yahoo Finance
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... By GuruFocus - Investing.com Canada
Durect: Q3 Earnings Snapshot - Houston Chronicle
Durect Corp Q3 2024 Earnings: GAAP EPS of -$0.14 Misses Estimates, Revenue at $1.9 Million Below Expectations - GuruFocus.com
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Durect reports Q3 EPS (14c), consensus (17c) - TipRanks
DURECT Q3: $4.3M Loss, Plans Phase 3 Trial Amid Funding Needs & License Agreement End | DRRX Stock News - StockTitan
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - StockTitan
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
DRRXDurect Corp Latest Stock News & Market Updates - StockTitan
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 - StockTitan
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ... - Yahoo Finance
Durect Corp Annual Meeting Decisions and Shareholder Votes - TipRanks
H.C. Wainwright maintains Neutral rating on Durect shares post FDA meeting - Investing.com
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - PR Newswire
BAT NE turnover rate (A), BAT temperature (B), representative BAT... - ResearchGate
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - StockTitan
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - PR Newswire
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update - Yahoo Finance
Durect Corp Stock (DRRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):